The Ministry of Health, Labor and Welfare (MHLW) sent an alert to doctors’ groups and prefectural authorities on January 28 about the risk of fulminant type 1 diabetes carried by Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab). The company revised its…
To read the full story
Related Article
- Add Type 1 Diabetes to Opdivo Label: MHLW
November 26, 2015
REGULATORY
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
April 17, 2026
- Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
April 17, 2026
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





